Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor

Although the study did not meet predetermined efficacy end point, single-agent alisertib was well tolerated by children with recurrent AT/RT, and SD or PR was observed in approximately a third of the patients.